Jin-Bo Gou

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Xu-Hua Guan, Yu-Hua Li et al. · The Lancet · 2020 · 1.3K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 237 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo et al. · The Lancet Respiratory Medicine · 2022 · 170 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Fengcai Zhu, Pengfei Jin, Tao Zhu et al. · Clinical Infectious Diseases · 2021 · 103 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17